A twice-yearly injection of this new drug can prevent high-risk populations from catching HIV. Now the EU has given it a green light.
Learn how lenacapavir works – and what its manufacturer, Gilead Sciences, is doing to broaden access to poorer countries.
Also hear from WinnieByanyima_, Executive Director of UNAidsglobal, on how the long-acting medication can help alleviate stigma and discrimination.
The World Economic Forum’s Health For All initiative aims to foster a world where everyone can access quality healthcare regardless of background or income.
A twice-yearly injection of this new drug can prevent high-risk populations from catching HIV. Now the EU has given it a green light.
Learn how #lenacapavir works – and what its manufacturer, Gilead Sciences, is doing to broaden access to poorer countries.
Also hear from WinnieByanyima_, Executive Director of UNAidsglobal, on how the long-acting medication can help alleviate stigma and discrimination.
The World Economic Forum’s Health For All initiative aims to foster a world where everyone can access quality healthcare regardless of background or income.
